Loading…
Loading grant details…
| Funder | European Commission |
|---|---|
| Recipient Organization | Chalmers Tekniska Hogskola Ab |
| Country | Sweden |
| Start Date | Oct 01, 2024 |
| End Date | Sep 30, 2028 |
| Duration | 1,460 days |
| Number of Grantees | 12 |
| Roles | Participant; Associated Partner; Coordinator |
| Data Source | European Commission |
| Grant ID | 101168851 |
Nucleic acid (NAs)-based therapies have started to yield major advances in the treatment of human disease.
New approaches for understanding NA structure and function are required to extend the boundaries of todays gene editing technologies, cancer therapies, and mRNA vaccines.
Single-molecule techniques have revolutionised our understanding of NAs and their interactions with therapeutic oligonucleotides, small molecules, and proteins.
However, for Europe to remain competitive in this area, new expertise is urgently required in single-molecule NA analysis, which intersects the fields of physical chemistry, biophysics, NA synthesis, and computation.
MeChaNiSM will train the next generation of European scientific leaders in the development and use of single-molecule biophysics techniques where they will investigate critical interrelated question regarding the structure, dynamics, function, and interactions of NAs.
To do this, our Doctoral Candidates (DCs) will:- Unravel high-resolution NA structures and intramolecular forces with modified bases- Understand the conformation and dynamics of NAs at the single-molecule level- Develop next-generation therapeutics for treating genetic diseasesMeChaNiSM connects world-leading researchers working in the fields of single-molecule biophysics, NA chemistry, and computational modeling with outstanding industrial partners working in complementary fields.
In addition to conducting world-class research, our DCs will understand industrial needs, have know-how in running multidisciplinary research, and will be immersed in a broad collaborative network connecting academia and industry.
Our DCs will provide vital future breakthrough applications in NAs and single-molecule analysis to pharmaceutical and biotechnological industries where the design of new drugs - including NA-based therapeutics and vaccine technologies - will provide major improvements to human health.
Stichting Vu; Dublin City University; Lumicks Bv; Nanotemper Technologies Gmbh; Astrazeneca Ab; Universitat Zu Koln; Universitat de Barcelona; Universitaet Augsburg; National Institute for Bioprocessing Research and Training Limited; Katholieke Universiteit Leuven; Universiteit Van Amsterdam; Chalmers Tekniska Hogskola Ab
Complete our application form to express your interest and we'll guide you through the process.
Apply for This Grant